https://www.selleckchem.com/products/VX-702.html
To assess long-term (up to 2years) efficacy, tolerability, and safety of erenumab for the prevention of episodic migraine (EM) in Japanese patients. Previously published results from the double-blind treatment phase (DBTP) of a phase 2 clinical study have demonstrated the efficacy and safety of erenumab in Japanese patients with EM. Patients completing the 24-week placebo-controlled DBTP could continue into the 76-week open-label treatment phase (OLTP), receiving erenumab 70 mg or 140mg subcutaneously once monthly. The initial dose in th
Like
Comment
Share
